

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 69661

Title: The dynamic monitoring of CEA, Ca 19-9 and inflammation-based indices in

patients with advanced colorectal cancer undergoing chemotherapy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04089095 Position: Editorial Board Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Serbia

Manuscript submission date: 2021-07-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-26 02:42

 $\textbf{Reviewer performed review: } 2021\text{-}08\text{-}05 \ 02\text{:}41$

Review time: 9 Days and 23 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscript conducted a observational study on the relationship between the dynamic change of CEA, Ca 19-9, inflammation-based indices and the response of chemotherapy in patients with advanced colorectal cancer, in order to replacing part of CT examinations. To some extent, this study is innovative, and the results obtained have certain clinical practicability. There are number of concerns with this report: Point 1: There is no abstract in the report. Point 2: P3 line7: "The exclusion criteria were age <18, resectable metastatic disease, patients unsuitable for RECIST 1.1 evaluation", is not necessary, because these criteria are indicated indirectly by the inclusion criteria mentioned above. Point 3: P3 line26: "Stable disease (SD) was defined as disease that did not meet the PD or PR criteria" shoud be "Stable disease (SD) was defined as disease that neither meet the PD nor PR criteria". Point 4: P6 line 2: For the first time UNL appears, please specify full name. Point 5: P7 line 13: "was obtained for CEA (0.842, p<0,01)", the comma should be changed to a decimal point. There are many similar errors in this article, please pay attention to the modification Point 6: In the note of Table 3: "** p>0.01" contradicts the text "p<0.01". Point 7: P9: Incorrect abbreviation in last paragraph: "the objective response rate (RR), the progression-free survival (PFS) rate, and the overall survival rate (ORR) in several studies." Point 8: P12 line18: "In our study, a CEA cut-off value of 60.85% with 100% Se and 35.7% Sp avoided 25% of CT control examinations in unresectable mCRC patients undergoing chemotherapy." The cut-off value "60.85%" is inconsistent with Table 4 "-60.85%". Point 9: What effect do different chemotherapy regimens have on tumor marker cut-off? Does the author consider an analysis?



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com